Loading
Histone Deacetylase Inhibitors Research / Epigenetics and DNA Methylation / Protein Degradation and Inhibitors · Journal article
International Journal of Molecular Sciences · September 9, 2026
Raises a question worth testing. It does not answer one.
This is an exploratory in vitro study demonstrating that ribitoborate and romidepsin produce synergistic effects on cell proliferation arrest and apoptosis in the MDA-MB-231 TNBC cell line. The work is mechanistic and hypothesis-generating, identifying potential molecular pathways but offering no evidence of efficacy in vivo or in patients.
In vitro cell line study. MDA-MB-231 triple-negative breast cancer cell line. Intervention: Ribitoborate and romidepsin combined treatment. Compared with: Ribitoborate alone, romidepsin alone, and untreated controls (implied).
Ribitoborate and romidepsin combination induced 80% cell proliferation arrest (p < 0.01) in MDA-MB-231 cells Combined treatment downregulated c-Myc, survivin, Bcl-2, and cyclin D1 and upregulated p53 and p21 more significantly than either agent alone Combined treatment time-dependently increased cell death with greater efficiency than romidepsin monotherapy
No in vivo efficacy, pharmacokinetics, toxicity, or maximum tolerated dose data provided
This in vitro finding is preliminary and does not yet support clinical application. Preclinical development would require validation in additional cell lines, in vivo xenograft models, and toxicity assessment before any consideration of clinical trials.
In vitro mechanistic study in a single TNBC cell line suggesting synergy between two agents, lacking any in vivo validation, patient data, or clinical trial evidence to support therapeutic application.
As stated by the source record.
Quoted from the source exactly as published.
This in vitro finding is preliminary and does not yet support clinical application. Preclinical development would require validation in additional cell lines, in vivo xenograft models, and toxicity assessment before any consideration of clinical trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Triple-negative breast cancer (TNBC) is a subtype associated with poor prognosis and low survival rates, largely due to limited treatment options. In recent years, histone deacetylase (HDAC) inhibitors have emerged as promising anti-cancer candidates due to their attractive epigenetic properties and distinct mechanisms of action but have shown limited success in solid tumors. Here, we explore ribitoborate along with HDAC inhibitors for potential use as a treatment for TNBC. Experiments were performed on the TNBC cell line MDA-MB-231. The results of the study revealed that ribitoborate and romidepsin showed synergistic responses leading to significant arrest of cell proliferation (80%) (p < 0.01) as well as migration inhibition. These effects were associated with downregulation of c-Myc, survivin, Bcl-2, and cyclin D1, as well as upregulation of p53 and p21 proteins; notably the changes were significantly greater with the combined treatment than with either ribitoborate or romidepsin alone. Romidepsin and ribitoborate combined treatment time-dependently increased cell death of MDA-MB-231 cells with greater efficiency than romidepsin alone. Cell death by apoptosis was supported by the upregulation of H3k9 and H3k27 acetylation with decreasing proliferation. These results suggest the great potential of the drug combination for treatment of TNBC. The underlying molecular mechanisms for synergy could be further explored for potential development of new combined therapy for breast cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.